Jan Käsler

Jan Käsler

Auto-generated profile, based on publicly available information

Jan Käsler

Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
OEOssia M. Eichhoff
Ossia M. Eichhoff
CSCorinne I. Stoffel
Corinne I. Stoffel
JKJan Käsler
Jan Käsler
LBLuzia Briker
Luzia Briker
PTPatrick Turko
Patrick Turko
MLMitchell Levesque
Mitchell Levesque
Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of patients due to resistance that arises through genetic, transcriptional, and metabolic adaptation. Identification of targetable vulnerabilities in NRAS-mutated melanoma could help improve patient treatment. Here, we used multiomics analyses to reveal that NRAS-mutated melanoma cells adopt a mesenchymal phenotype with a quiescent metabolic program to resist cellular stress induced by MEK inhibition. The metabolic alterations elevated baseline reactive oxygen species (ROS) levels, leading these cells to become highly sensitive to ROS induction. In vivo xenograft experiments and single-cell RNA sequencing demonstrated that intratumor heterogeneity necessitates the combination of a ROS inducer and a MEK inhibitor to inhibit both tumor growth and metastasis. Ex vivo pharmacoscopy of 62 human metastatic melanomas confirmed that MEK inhibitor–resistant tumors significantly benefited from the combination therapy. Finally, oxidative stress response and translational suppression corresponded with ROS-inducer sensitivity in 486 cancer cell lines, independent of cancer type. These findings link transcriptional plasticity to a metabolic phenotype that can be inhibited by ROS inducers in melanoma and other cancers. Significance: Metabolic reprogramming in drug-resistant NRAS-mutated melanoma cells confers sensitivity to ROS induction, which suppresses tumor growth and metastasis in combination with MAPK pathway inhibitors.

31 March 2023
Verified
Other
Open access
OEOssia M. Eichhoff
Ossia M. Eichhoff
CSCorinne I. Stoffel
Corinne I. Stoffel
JKJan Käsler
Jan Käsler
LBLuzia Briker
Luzia Briker
PTPatrick Turko
Patrick Turko
MLMitchell Levesque
Mitchell Levesque
S16: scRNA-sequencing analysis of xenograft tumors M130227

31 March 2023
Verified
Other
Open access
OEOssia M. Eichhoff
Ossia M. Eichhoff
CSCorinne I. Stoffel
Corinne I. Stoffel
JKJan Käsler
Jan Käsler
LBLuzia Briker
Luzia Briker
PTPatrick Turko
Patrick Turko
MLMitchell Levesque
Mitchell Levesque
S10: Clinical data of orthologic slice cultures

31 March 2023
Verified
Other
Open access
OEOssia M. Eichhoff
Ossia M. Eichhoff
CSCorinne I. Stoffel
Corinne I. Stoffel
JKJan Käsler
Jan Käsler
LBLuzia Briker
Luzia Briker
PTPatrick Turko
Patrick Turko
MLMitchell Levesque
Mitchell Levesque
Table ST1: Summary of growth inhibitory IC50 values (including the corresponding 95% confident intervals (C.I.95%) conducted for neocuproine or MEKi (binimetinib) and primary human cell lines. The table includes the confirmed oncogenic mutation as well as the ratio of neocuproine normalized to the MEKi response.

31 March 2023
Verified
Other
Open access
OEOssia M. Eichhoff
Ossia M. Eichhoff
CSCorinne I. Stoffel
Corinne I. Stoffel
JKJan Käsler
Jan Käsler
LBLuzia Briker
Luzia Briker
PTPatrick Turko
Patrick Turko
MLMitchell Levesque
Mitchell Levesque
Table ST3: Differential expressed RNA transcripts between MEKi-sensitive and -resistant melanoma cell cultures.